Ann: Quarterly Activity Report & Appendix 4C, page-12

"This open label Phase 1/2 trial will recruit approximately 60 patients with 18F-FDG PET/CT imaging-identified extramedullary AML at 10 clinical sites across Australia using a two-stratum (arm) design. "

Its unfortunate that we have been unable to recruit any patients, as our data tells us the outcomes would be promising.
Nothing was mentioned about European sites either. Very surprising that we haven't secured a European site in nearly 12 months since the Aus trial opened.
I certainly don't see how we will recruit 60 patients at this rate.